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BACKGROUND: Tumour cell lysates are an excellent source of many defined and undefined tumour antigens and have been used
clinically in immunotherapeutic regimes but with limited success.
METHODS: We conjugated Mel888 melanoma lysates to rabbit haemorrhagic disease virus virus-like particles (VLP), which can act as
vehicles to deliver multiple tumour epitopes to dendritic cells (DC) to effectively activate antitumour responses.
RESULTS: Virus-like particles did not stimulate the phenotypic maturation of DC although, the conjugation of lysates to VLP (VLP-lysate)
did overcome lysate-induced suppression of DC activation. Lysate-conjugated VLP enhanced delivery of antigenic proteins to DC,
while the co-delivery of VLP-lysates with OK432 resulted in cross-priming of naı¨ve T cells, with expansion of a MART1þ population of
CD8þ T cells and generation of a specific cytotoxic response against Mel888 tumour cell targets. The responses generated with VLP-
lysate and OK432 were superior to those stimulated by unconjugated lysate with OK432.
CONCLUSION: Collectively, these results show that the combination of VLP-lysate with OK432 delivered to DC overcomes the
suppressive effects of lysates, and enables priming of naı¨ve T cells with superior ability to specifically kill their target tumour cells.
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Immunotherapy of melanomas is an area of great current clinical
interest, owing to the immunogenic nature of melanomas and the
identification of many defined tumour antigens (Kawakami et al,
1994; Romero et al, 2002). Many therapeutic strategies have
centred around the activation of cytotoxic T lymphocytes (CTLs)
to produce high levels of IFN-g and specific cytolytic activity.
Strategies for inducing tumour-specific CTL in vivo have utilised
adjuvant-activated dendritic cells (DC) pulsed with melanoma
peptides or tumour lysates, either delivered directly to patients or
used for ex vivo activation of autologous T cells for adoptive
transfer (Dudley et al, 2005; Fang et al, 2008). Although these
approaches have been used in clinical trials, they have yielded
modest benefits for patients to date, suggesting that modifications
to these strategies may improve the specificity and potency of
antitumour immune responses (Hershey et al, 2002; Salcedo et al,
2006; Hong et al, 2010).
The use of DC pulsed with tumour lysates and activated with an
adjuvant is thought to result in limited responses because of
the induction of tolerance in the context of DC–tumour intera-
ctions (Mehrotra et al, 2003). This may in part be due to the
inhibitory nature of lysates on the concomitant activation of DC as,
for example, DC pulsed with lysates and matured with the
potent bacterial adjuvant OK432 have been shown to secrete less
cytokines and have lower expression of MHC-II and costimulatory
molecules than unpulsed DC matured with OK432 (Hatfield
et al, 2008).
Virus-like particles (VLP) are a candidate vaccine with the
potential to enhance the immunogenicity of tumour lysate proteins,
as they can act as vehicles for the delivery of heterologous antigens
to DC, leading to the generation of strong cytotoxic T-cell responses
(Storni et al, 2004; Qiao et al, 2006). Virus-like particles are formed
from viral capsid proteins and are stable, non-replicative and highly
immunogenic, making them a safe option for the treatment of
cancer patients. Model tumour antigens either chemically coupled
to rabbit haemorrhagic disease virus virus-like particles (RHDV
VLP) or recombinantly expressed within the particles, have shown
strong efficacy in vivo using murine models of melanoma (Peacey
et al, 2008).
Previous studies have demonstrated that RHDV VLP conjugated
to tumour lysates are cross-presented by human DC to induce
strong CD8þ T-cell responses in vitro, although, murine DC have
shown no evidence of activation by VLP (Win et al, 2011). Cross-
presentation of tumour antigens is an important prerequisite for
the development of activated T cells with cytotoxicity against
tumour cells, although DC induce more potent cytotoxic T-cell
responses when they have been optimally matured (Storni et al,
2002; Keller et al, 2010).
Here, we demonstrate that VLP conjugated to tumour cell
lysates are able to induce specific immune responses towards
tumour cells, while negating the inhibitory effects of lysates
delivered alone. This is achieved through enhanced delivery of
antigen and cross-presentation capabilities of DC, and is further
dependent on the addition of an adjuvant to ensure effective DC
maturation and priming of naı¨ve T-cell responses.
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MATERIALS AND METHODS
Generation and coupling of Mel888 lysates to VLP
Conjugation of Mel888 tumour cell lysates to RHDV VLP was
carried out as previously described (Peacey et al, 2007; Win et al,
2011). Mel888 tumour cells (Cancer Research UK) were grown in
DMEM with 10% FCS and 1% L-glutamine and lysates were made
by three repeat cycles of freeze–thaw lysis in the presence of
complete mini EDTA-free protease inhibitor tablets (Roche
Diagnostics Ltd, Mt Wellington, New Zealand). Cells were
routinely tested for Mycoplasma and found to be free of infection.
Lysates were mixed with a 10-fold molar excess of the hetero-
bifunctional linker sulfo-succinimidyl 4-(N-maleimidomethyl)
cyclohexane-1-carboxylate (sulfo-SMCC) (Pierce, Rockford, IL,
USA) in phosphate buffer pH 7.3 followed by dialysis to remove
unbound chemical linker. Virus-like particle were reacted with a
10-fold molar excess of N-succinimidyl S-acetylthioacetate (SATA)
(Pierce) followed by treatment with 100 mg hydroxylamine.HCl
(Sigma, Dorset, UK) per ml of protein. Thiol-activated VLP were
passed through a HiTrap desalt column (GE Healthcare, Bucks,
UK) to remove unbound SATA. Equal concentrations of thiol-
activated VLP and malemide-activated lysates were mixed together
for 1 h. Coupling was confirmed using sodium dodecyl sulphate-
polyacrylamide gel (SDS–PAGE) containing 10% or 15% acryl-
amide and western blotting using polyclonal rabbit anti-VLP
and monoclonal human anti-MART-1 antibodies (clone M2-7C10;
Serotec, Oxon, UK).
Preparation of monocyte-derived DCs
The white blood cell fraction from apheresis blood products
(National Blood Service, Leeds, UK) was separated using
Lymphoprep (Axis-Shield, Dundee, Scotland, UK) gradients
and CD14þ monocytes were selected with a MACS column
using anti-CD14 magnetic beads (Miltenyi Biotec, Surrey, UK).
The CD14þ cells were cultured for 5 days in RPMI (Sigma)
containing 10% FCS with 800 U ml – 1 GM-CSF and 500 U ml – 1
IL-4 (R&D Systems, Abingdon, UK) at 37 1Cþ 5% CO2 (Errington
et al, 2008).
DC activation
Dendritic cells were exposed to 50 mg ml – 1 VLP-Mel888 lysates,
Mel888 lysates or left un-stimulated for 4 h before the addition of
10 mg ml – 1 OK432 (Chugai Pharmaceutical Co., Ltd, Tokyo, Japan)
for 24 h at 37 1Cþ 5% CO2. Cell staining was performed using anti-
CD11c-APC and PE-conjugated monoclonal antibodies directed
against epitopes of CD40, CD80, CD86 and HLA-DR. Dendritic
cells were incubated with the respective antibodies or IgG isotype
control antibodies and fluorescence was measured using a
FACSCalibur (BD Biosciences, Oxford, UK). Supernatants were
collected and assayed for the presence of IL-12p70, CCL5, IL-6 and
TNF-a by ELISA using matched antibodies (BD Biosciences).
Subcellular fractionation
Dendritic cells (2 106 ml – 1) were incubated with VLP, Mel888
lysate or VLP-Mel888 lysate (50 mg ml – 1) for either 1 or 3 h. After
three washes in ice-cold PBS (pH 6.8), cell pellets were re-
suspended in 1 ml homogenisation buffer (HB; PBS, 0.25 M sucrose,
10 mM Tris, 1 mM EDTA with protease inhibitors and DNase
(Complete – Roche Diagnostics, Sussex, UK), pH 6.8) and gently
homogenised with a cell-cracker (HGM laboratory equipment).
Postnuclear supernatant was prepared by centrifugation of crude
lysis at 1000 g for 10 min at 4 1C. The supernatant was moved
to a new microfuge tube. Light membranes (recycling and
early endosomes) were separated from heavy membranes (late
endosomes and lysosomes) by centrifugation at 8000 g for
20 min at 4 1C. The post-8000 g supernatant was adjusted to 40%
(w/v) sucrose using a stock of 80% (w/v) sucrose in HB to a final
volume of 4 ml. This was overlayed with a 4 ml volume of 35% (w/
v) sucrose in HB, followed by a 4 ml volume of 5% (w/v) sucrose in
HB. Recycling endosomes were separated from early endosomes by
ultracentrifugation at 180 000 g for 16 h at 4 1C. The top 3 ml was
discarded. The next 5 ml (recycling endosomes) was washed with
PBS (pH 6.8) and pelleted by ultracentrifugation at 144 651 g for
2 h at 4 1C. The last 4 ml from the separation (early endosomes)
was washed with PBS (pH 6.8) and pelleted by ultracentrifugation
at 144 651 g for 2 h at 4 1C. The post-8000 g pellet was re-
suspended in 4 ml HB containing 10% Percoll and loaded on top of
6 ml of HB containing 45% Percoll. Late endosomes and lysosomes
were separated by ultracentrifugation at 50 000 g for 1 h at 4 1C. The
top 4 ml (late endosomes) was washed with PBS (pH 6.8) and pelleted
by ultracentrifugation at 144 651 g for 2 h at 4 1C. The bottom 4 ml
(lysosomes–late endosome fusions) was washed with PBS (pH 6.8)
and pelleted by ultracentrifugation at 144 651 g for 2 h at 4 1C.
SDS–PAGE and immunoblotting
Cellular fractions were routinely analysed on 12.5% SDS– PAGE in
the presence of 0.1% SDS using the buffer system of Laemmli
(1970). Polypeptide bands were visualised using Simply Blue
Safe Stain (Invitrogen, Paisley, UK). During immunoblotting,
membrane vesicles were subjected to 12.5% SDS– PAGE followed
by electroblotting onto a polyvinylidene difluoride membrane
including 0.02% SDS in the running buffer. Cell fractions were
probed using rabbit-derived serum against RHDV-VLP and antibodies
against MART1 (Serotec), LAMP-1 (clone 25, BD Biosciences),
EEA1 (clone 14, BD Biosciences), Rab11 (clone 47, BD Biosciences)
and Rab7 (clone 117, Abcam, Cambridge, UK). Horseradish
peroxidase-conjugated goat-derived anti-mouse secondary antibody
was used for detection (Invitrogen). The antibody-specific bands
were visualised using the SuperSignal West Pico chemiluminescence
system (Pierce).
Protein assay
Protein concentrations were determined using a bicinchoninic
acid protein assay kit (Sigma) with bovine serum albumin as
the standard.
Naı¨ve T-cell priming
HLA-A2þ DC (1 106 cells ml – 1) were harvested and pulsed with
50 mg ml – 1 VLP, Mel888 lysate or VLP-Mel888 lysate for 4 h before
the addition of 10 mg ml – 1 OK432 overnight. The DC were washed
and cultured with PBMC at a ratio of 15–40 : 1 (PBMC:DC) in CTL
media (RPMI with 1% non-essential amino acids, 1% L-glutamine,
1% sodium pyruvate, 1% HEPES, 20 mM 2-mercaptoethanol and
7.5% human serum (Sigma)) containing 10 mg ml – 1 IL-7 (R&D
Systems) for 7 days at 37 1Cþ 5% CO2. After 4 days, 30 U ml – 1 of
IL-2 (R&D Systems) was added to the CTL cultures. After 7 days,
fresh DC pulsed with VLP, Mel888 lysate or VLP-Mel888 lysate
were added and cultured for a further 7 days. The CTL were then
assessed for their specificity and cytotoxic activity against Mel888
target cells with ovarian tumour cells, SKOV-3, used as irrelevant
target cells.
MART1 pentamer staining
CTL (1 106 cells) were labelled with APC-conjugated ELAGIGILTV
pentamer (F082-4A, ProImmune, Oxford, UK), FITC-conjugated
anti-CD8 and PE-conjugated anti-CD19 antibodies or respective
IgG isotype controls (BD Biosciences). The cells were analysed by
flow cytometry.
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Cytotoxicity assay
T-cell cytotoxicity was measured by 51Cr release where target
cells (5000 cells per well) were labelled with 100mCi 51Cr (Perkin
Elmer, Cambridge, UK) for 1 h then washed three times in RPMI
containing 10% FCS and 1% L-glutamine. Labelled cells were then
incubated with cold Daudi cells (5000 cells per well, to quench
nonspecific killing) and CTL at different effector:target ratios.
After 4 h, the cells were pelleted and 50 ml of supernatant was
transferred to scintillation plates (Perkin Elmer) and left to dry
overnight. Levels of 51Cr were measured in the supernatants using
a Wallac Jet 1459 Microbeta Scintillation counter and Microbeta
Windows software (Perkin Elmer).
Percent specific lysis was calculated by the following formula:
% specific lysis ¼ðsample c:p:m: spontaneous c:p:m:Þ
=ðmaximum c:p:m: spontaneous c:p:m:Þ100
CD107 and IFN-c release
Cytotoxic T lymphocytes (2.5 105 cells) were cultured with target
cells at a 1 : 1 ratio for 1 h at 37 1C before the addition of FITC-
conjugated anti-CD107a and CD107b antibodies (BD Biosciences),
and 10mg ml – 1 brefeldin A (Sigma) or 10 mg ml – 1 brefeldin A only.
The cells were incubated for a further 4 h before co-staining with
PerCP-conjugated anti-CD8 antibodies (BD Bioscences) for 30 min.
The CD107a/b-labelled cells were fixed in 1% paraformaldehyde
(Sigma) and analysed by flow cytometry while the additional set
were stained for intracellular IFN-g (BD Bioscences). These cells
were fixed in 1% paraformaldehyde before permeabilising in 0.3%
saponin (Sigma) for 30 min and stained with FITC-conjugated
anti-IFN-g. The cells were washed and analysed immediately by
flow cytometry.
Statistical analyses
Student’s two-tailed paired t-tests were performed where statistics
are shown using GraphPad Prism version 5.0b (La Jolla, CA, USA).
Significance was assigned where P-values were 0.05 or less.
RESULTS
RHDV VLP require the addition of an adjuvant to mature
DC, although conjugation of tumour cell lysates to VLP
overcomes the inhibitory effects of lysates on DC
maturation
Activation of cytotoxic T-cell responses requires DC to deliver
antigen-specific signals to T cells by way of MHC-I:peptide ligation
of the TCR, while also providing costimulatory molecule engage-
ment and secretion of appropriate cytokines. Only upon matura-
tion, or activation, do DC provide the necessary levels of
costimulation and cytokines to induce activation and expansion
of their cognate T cells (Mescher et al, 2006).
Previous studies demonstrated that RHDV VLP do not result in
the phenotypic activation of DC in vitro, so we also included an
adjuvant to enhance the antigen presentation capacity of VLP-
lysate-loaded DC. OK432 was chosen as a suitable adjuvant, as it
has been shown to activate human monocyte-derived DC and is
licensed for clinical use (Hovden et al, 2011). OK432 is a
preparation of a penicillin-killed, low virulence strain of strepto-
coccus pyogenes (group A) and has been used as an immuno-
therapeutic agent in a number of malignancies without significant
clinical side effects. The antitumour effects of OK432 are thought
to be mediated by the activation of a variety of effector cells,
presumably including DC (Kuroki et al, 2003).
Human DC were pulsed with VLP conjugated to Mel888 lysates
(VLP-lysate) or lysates, either alone or with OK432 before staining
for surface markers of activation (Figure 1) and determining the
cytokine secretion profiles of these cells (Figure 2).
Dendritic cells pulsed with VLP-lysate or lysates without
adjuvant did not activate DC to increase expression of MHC-II,
CD40, CD80 or CD86, nor did they induce secretion of the
proinflammatory cytokines IL-12, IL-6 and TNF-a or the
chemokine CCL5. Conversely, the addition of OK432 induced
clear increases in MHC-II and costimulatory molecules on the
surface of the DC, while also inducing high levels of proin-
flammatory cytokine and CCL5 secretion.
Interestingly, lysates delivered with OK432 resulted in decreased
MHC-II and costimulatory molecule expression and cytokines
compared with DC pulsed with OK432 alone. We have previously
found this inhibitory effect of lysates on adjuvant-induced
activation of DC in both murine and human systems (Hatfield
et al, 2008; unpublished data). However, this inhibition was not
seen when VLP were conjugated to the lysates, suggesting that the
inhibitory effects of lysates on adjuvant-induced activation of DC
is reversed by the presence of VLP.
Conjugation of tumour cell lysates to VLP enables more
efficient delivery of tumour antigens to DC compartments
for processing
One of the requirements of successful tumour immunotherapy is
ensuring efficient delivery of therapeutic antigens to DC in a
manner resulting in epitope presentation conducive to the
development of cytotoxic T-cell responses. Previous studies have
demonstrated that immunogenic peptides or tumour cell lysates
conjugated to VLP are cross-presented to CD8þ T cells by DC
more effectively than peptide or lysates delivered alone; however,
the reasons underpinning this effect are not well defined (Win
et al, 2011). To further understand the efficiency of antigen
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Figure 1 Conjugation of tumour lysates to VLP negates their inhibitory
effects DC phenotypic maturation. Bar graphs represent (A) MHC-II,
(B) CD40, (C) CD80 and (D) CD86 expressed on DC alone or pulsed
with Mel888 Lysates (Lysate) or VLP-Mel888 Lysates (VLP-Lysate) 4 h prior
to the addition of no adjuvant (grey bars) or OK432 (black bars) for 24 h.
Data represents mean±SD for 6 individual donors. *Denotes statistical
significance (Po0.05) between lysate-pulsed and unpulsed DC.
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delivery and the intracellular trafficking of these antigens, DC
pulsed with lysates, VLP or lysates conjugated to VLP were
fractionated into their constituent subcellular compartments and
probed for the presence of VLP or lysate.
To confirm the subcellular compartments, an initial DC
fractionation was carried out separating early endosomes (EE),
late endosomes (LE), lysosomes (Lys) and recycling endosomes
(RE) into discrete compartments (Figure 3A). Western blot
analysis identified a single band for each of EEA1, Rab7, LAMP1
or Rab11, defining the EE, LE, Lys and RE compartments
respectively.
Dendritic cells were then pulsed with VLP, VLP-lysate or lysate
alone for 1 or 3 h, and washed to remove excess antigen. The DC
were subjected to fractionation into their constituent subcellular
compartments and probed by western blot for the presence of the
VLP VP60 protein or the Mel888 lysate protein MART1 (Figures
3B–D). The resultant blots show that VLP were delivered
effectively to DC, as entire VP60 protein was present in EE, LE
and Lys, but not RE, after both 1 and 3 h. Interestingly, no MART1
was detected in any of the endosomal fractions at either time
point when lysates delivered alone were the source of antigen;
however, MART1 from VLP-conjugated lysates was detected in
large molecular weight complexes at both 1 and 3 h after delivery
to DC. MART1 was present in both EE and LE, and to a lesser
degree Lys, at both time points. Additionally, at 1 h a small band of
20–30 kDa was seen in the lysosomal fraction, indicating degrada-
tion of the higher molecular weight MART1-containing complexes
into single MART1 molecules. It is likely that reduced amounts of
protein being detected in Lys, and none in RE, is due to degraded
forms of the VP60 or MART1 proteins being undetectable by their
antibodies. These results indicate that conjugation of lysates to
VLP enables more efficient delivery and retention of the antigenic
proteins in antigen processing compartments by DC, than lysates
delivered alone.
Delivery of VLP conjugated to tumour cell lysates together
with an adjuvant enables cross-priming of naı¨ve CD8þ
T-cell responses
Activation and expansion of T cells expressing TCRs specific for
melanoma antigens from circulating naı¨ve T cells is essential for
achieving adaptive cytolytic activity against tumour cells, while
ensuring that tumour cells are the exclusive targets of any
stimulated CTL. Activating CTL against one melanoma epitope,
using single peptide therapies, can achieve significant death of
target tumour cells, but can also lead to tumour escape whereby
tumour cells that do not express that specific antigen continue
to grow (Sanchez-Perez et al, 2005). Thus, it is desirable to
incorporate many tumour antigens into a DC-based vaccine,
so CTL that recognise diverse tumour epitopes can be activated
and expanded to prevent tumour escape. To achieve this,
VLP conjugated to Mel888 tumour cell lysates or lysates alone
were pulsed onto DC with the adjuvant OK432, or with no
maturation stimulus and used to prime naı¨ve T-cell responses
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Figure 3 Conjugation of lysates to VLP enhances delivery of tumour
antigens to DC antigen processing compartments. (A) Subcellular fractions
containing early endosomes (EE), late endosomes (LE), lysosomes (Lys) or
recycling endosomes (RE) were prepared from DC. The following probes
were used as markers of specific subcellular compartments; EEA1 (EE),
Rab7 (LE), LAMP1 (Lys) and Rab11 (RE). (B) Dendritic cells were
incubated with VLP for 1 or 3 h. After washing, subcellular fractions were
prepared and the presence of VLP was analysed by western blot using anti-
VP60 antibodies. (C) Dendritic cells were incubated with lysate for 1 or 3 h.
After washing, subcellular fractions were prepared and the presence of
MART1 was analysed by western blot. (D) Dendritic cells were incubated
with VLP-lysate for 1 or 3 h. After washing, subcellular fractions were
prepared and the presence of MART1 was analysed by western blot.
Results are representative of four independent experiments.
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Figure 2 Conjugation of tumour lysates to VLP negates their inhibitory
effects on DC cytokine/chemokine production. Bar graphs represent (A)
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against Mel888 tumour cells using established methodology
(Errington et al, 2008).
To determine the expansion of CTL toward a defined melanoma
antigen, the primed cells were stained with a MART-1 pentamer.
This demonstrated that antigen-specific T cells were successfully
expanded when VLP-lysate or lysates were pulsed onto DC with
OK432 (Figure 4). The use of VLP-lysate with OK432 led to greater
expansion of MART1-specific T cells than loading DC with
unconjugated lysates and OK432. Moreover, VLP-lysate/OK432
primed a population of CTL able to specifically degranulate
against, produce IFN-g on recognition of, and directly lyse Mel888
tumour cells to a greater degree than unconjugated lysates/OK432
(Figure 5). Interestingly, the amount of unconjugated lysate pulsed
on to DC (50 mg ml – 1) was the same amount as total VLP-lysate
added where VP60 protein constitutes at the very least half of the
total protein delivered. Although it is not well defined exactly
which proteins are bound to the VLP, it is likely that the efficiency
of this coupling and size constraints limit conjugation of lysate
proteins, such that lysate delivered on VLP equates quantitatively
to less tumour antigenic protein than pulsing DC with unconju-
gated lysate by at least half. This suggests that VLP-lysates are
particularly efficient at delivering antigens to DC for cross-
presentation to T cells.
DISCUSSION
Virus-like particles carrying tumour antigens are able to improve
the survival and delay the growth of tumours in mice with
concomitant in vivo cytotoxicity (Peacey et al, 2008). However, it is
crucial to translate these findings into human systems to further
understand how human immune cells may interact with VLP to
generate cytotoxic responses effective in melanoma patients.
Dendritic cells pulsed with VLP conjugated to tumour lysates
did not result in phenotypic activation or proinflammatory cytokine
secretion above the levels seen with unpulsed DC. This may be due
to the lack of nucleic acid within the VLP acting as a pathogen-
associated molecular pattern used by cells to recognise viruses
through ligation of pattern recognition receptors. However, the
addition of an adjuvant, streptococcal-derived OK432, induced
maturation of DC with secretion of the proinflammatory cytokines
that favour the development of a Th1, cytotoxic immune response.
Consistent with current literature in a murine model (Hatfield
et al, 2008), the use of lysates derived from tumour cells by way of
freeze and thaw cycles was shown to be inhibitory to DC, an effect
that is only partially restored with the addition of a maturation
stimulus (note in Figures 1 and 2 the reduced activation of DC by
OK432 in the presence, compared with the absence, of lysate).
However, the mechanism(s) responsible for this lysate inhibition
have yet to be fully elucidated. It has been disputed whether a
particular mode of cell death will lead to immune cell activation or
suppression, with many reports suggesting that necrotic cell death,
similar to that seen when preparing lysates by freeze thaw, is more
stimulatory than apoptosis (Strome et al, 2002; von Euw et al,
2007; Herzog et al, 2011). One factor missing from the ‘necrotic’
cell death induced by freeze–thaw lysis, however, is the induction
of stress related molecules such as heat shock proteins, which can
act as danger signals for immune activation (Flohe et al, 2003;
Bendz et al, 2007; Aguilera et al, 2011). Therefore, the inhibitory
nature of lysates may be an inevitable consequence of their method
of preparation, although lysates remain highly practical as a source
of multiple tumour-associated antigens for clinical application.
Interestingly, the delivery of tumour cell lysates conjugated to
VLP, in contrast to unconjugated lysate, did not reduce the ability
of DC to activate in the presence of OK432. There are two possible
explanations for this observation. First, tumours contain many
immunosuppressive molecules, which may not be preferentially
coupled to VLP and second, VLP may be altering the intracellular
fate of the lysate proteins coupled to their surface to facilitate their
immunostimulatory access to the antigen processing pathways
within DC.
To confirm that conjugation of lysates to VLP enables more
effective presentation, DC were fractionated into their constituent
endosomal compartments and analysed for the presence of VLP
or lysate-derived proteins (MART1). The resultant blots show
lysates are delivered more effectively to DC, and are retained
in the endosomal system for longer, when conjugated to VLP.
Consistent with our previous studies defining the mechanisms
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of cross-presentation of VLP by DC, the VLP and VLP-conjugated
antigen were found in early and late endosomes and lysosomes,
indicating that VLP are degraded into antigenic peptides within
lysosomal compartments. In contrast, when lysates were delivered
alone, no MART1 was detected in any endosomal fractions, despite
delivering more than double the amount of lysate protein than
would be conjugated to VLP. This suggests that unconjugated lysate
proteins are either not taken up to a detectable level, or that these
proteins are rapidly degraded by the DC, both situations resulting
in reduced cross-presentation and cytotoxic responses. Recycling
endosomes were not shown to contain any VLP or lysate-derived
MART1, although this is not surprising, as the degradation of VP60
or MART1 into peptides would prevent the antibodies directed
against the entire protein from recognising them.
Developing effective cytotoxic T-cell responses against tumour
cells is one key step towards destroying them. Ensuring naı¨ve
T cells are primed for activity specifically against their tumour cell
target is essential to prevent autoimmunity, while priming a pool
of T cells recognising a variety of tumour antigens is important for
achieving maximal tumour killing and preventing escape variants.
To this effect, DC pulsed with VLP conjugated to melanoma cell
lysates and matured with OK432 were able to cross-prime naı¨ve
T cells, with associated increases in the numbers of MART1-
specific, IFN-g producing, degranulating CD8þ T cells. Most
importantly, these expanded CTL were cytotoxic against the
tumour cells from which the lysates were originally derived. In all
instances, the delivery of lysates conjugated to VLP to DC resulted
in more pronounced cytotoxic T-cell responses than delivery of
lysates alone, despite delivering significantly less tumour antigen
on conjugation to VLP.
We propose that this superior T-cell cross-priming ability
conferred by VLP is likely due to more efficient uptake than cell
lysates alone, leading to a greater density of tumour associated
peptides being displayed on the DC surface. Virus-like particles
conjugated to antigens require endosomal processing by DC before
peptide display on MHC-I, whereas peptides do not. Faure et al
(2009) demonstrated that sustained antigen cross-presentation was
observed where antigens required processing before presentation,
despite less antigen being presented directly after the initial pulse
(Faure et al, 2009). Short peptides were loaded directly onto
MHC-I molecules favouring rapid presentation, but this response
did not last 424 h. The long peptides that required processing
were still being presented 3 days after initial pulsing, despite
significant washing steps to remove any free peptides, a phenom-
enon potentially due to antigen storage compartments inside DC.
This also may be true for VLP and their derivative peptides, as they
are degraded in lysosomes before loading onto MHC-I that have
recycled from the cell surface. Presumably, this exchange of
peptide occurs in a post-lysosomal compartment that may serve as
a reservoir for antigen cross-presentation over a sustained period
of time. In the case of the lysates, we have shown that the addition
of these to VLP prevents their inhibitory effects on DC activation.
This together with increased delivery of lysate antigens to
compartments where efficient cross-presentation can take place,
may explain why T cells, which have interacted with VLP-lysate
pulsed DC and matured with an adjuvant, are more effectively
primed for cytotoxicity.
Tumour cell lysates have been used clinically with encouraging,
though limited success (Jocham et al, 2004). The results presented
here suggest that conjugation of tumour cell lysate proteins to VLP
provides an excellent scaffold for the delivery of tumour-derived
antigens to DC. The simple conjugation process is flexible enough
to enable the addition of any tumour lysate to VLP quickly and
efficiently, both key factors in transferring this antigen delivery
platform into a potential clinical setting. The addition of an
adjuvant to the DC is required for optimal priming of specific
cytotoxic T-cell responses, although there remains scope for
incorporating both antigen and adjuvant into the same VLP for
more effective therapy and ease of use.
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